Targets › MELK
2 programs from 2 companies in 2 trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Sep 2027.
Serine/threonine-protein kinase involved in various processes such as cell cycle regulation, self-renewal of stem cells, apoptosis and splicing regulation. Has a broad substrate specificity; phosphorylates BCL2L14, CDC25B, MAP3K5/ASK1 and ZNF622. (UniProt, Q14680)
Open in Phaseline: the race on MELK, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Delcath Systems | Melphalan/HDS High-dose melphalan delivered directly to the liver via hepatic artery infusion | MELK | Phase 2 | Metastatic Breast Cancer in the Liver | May 2029 |
| OncoTherapy Science | OTS167PO MELK kinase inhibitor | MELK | Phase 1 | Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer | Sep 2027 |
Metastatic Breast Cancer in the Liver (1) Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.